Time course of action of sugammadex (Org 25969) on rocuronium-induced block in the Rhesus monkey, using a simple model of equilibration of complex formation.

BACKGROUND Reversal of neuromuscular block can be accomplished by chemical encapsulation of rocuronium by sugammadex (Org 25969), a synthetic gamma-cyclodextrin derivative. The present study determined the time course of the reversal action of sugammadex on rocuronium-induced block in the anaesthetized Rhesus monkey using train-of-four stimulation. METHODS A bolus injection of rocuronium 100 microg kg(-1) (about 1xED(90)) was given to determine the degree of neuromuscular block reached by this dose. After complete spontaneous recovery, a rapid bolus injection of sugammadex, 1 mg kg(-1), was given and at different time intervals (15, 30 or 60 min, in three different experiments) the effect of another rocuronium bolus injection of 100 microg kg(-1) was determined. RESULTS Injection of the first dose of rocuronium resulted in a mean neuromuscular block (depression of first twitch) of 93 (SEM=1.6)%. Fifteen minutes after injection of sugammadex the same rocuronium dose resulted in 17% (SEM=5.6) block. After 30 and 60 min these maximum blocks amounted to 49% (SEM=7.6) and 79% (SEM=4.2), respectively. The estimated half-life of sugammadex in Rhesus monkey is 30 (SEM=4.9) min. CONCLUSIONS The half-life of sugammadex (Org 25969), a new fast and efficient reversal agent for rocuronium-induced block, is relatively short in the Rhesus monkey, implying the possibility to perform neuromuscular block by rocuronium shortly after reversal of a prior block. In translation to the human situation differences in rocuronium sensitivity and kinetics should be taken into account.

[1]  J. van Egmond,et al.  Reversal of Profound Rocuronium Neuromuscular Blockade by Sugammadex in Anesthetized Rhesus Monkeys , 2006, Anesthesiology.

[2]  J. van Egmond,et al.  Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. , 2006, British journal of anaesthesia.

[3]  J. van Egmond,et al.  Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys. , 2006, British journal of anaesthesia.

[4]  M. Giovannelli,et al.  Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. , 2006, British journal of anaesthesia.

[5]  S. Ramael,et al.  First Human Exposure of Org 25969, a Novel Agent to Reverse the Action of Rocuronium Bromide , 2005, Anesthesiology.

[6]  P. Desmond,et al.  Liquid chromatography/mass spectrometric bioanalysis of a modified gamma-cyclodextrin (Org 25969) and Rocuronium bromide (Org 9426) in guinea pig plasma and urine: its application to determine the plasma pharmacokinetics of Org 25969. , 2002, Rapid communications in mass spectrometry : RCM.

[7]  S. Ramael,et al.  Preliminary Assessment of Org 25969 as a Reversal Agent for Rocuronium in Healthy Male Volunteers: [2002][A-1008] , 2002 .

[8]  J. Egmond,et al.  Reversal agents for nondepolarizing neuromuscular blockade: Reasons for and development of a new concept , 2002 .

[9]  Mark Bradley,et al.  A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. , 2002, Angewandte Chemie.

[10]  R. Mirakhur,et al.  Postoperative residual block after intermediate‐acting neuromuscular blocking drugs , 2001, Anaesthesia.